Breakthrough Pain: Improving Recognition and Management to Enhance Quality of Life CME/CE

Author Information and Disclosures

Release Date: March 31, 2008; Valid for credit through March 31, 2009

Credits Available
Physicians - maximum of 1.25 AMA PRA Category 1 Credit(s)™ for physicians;
Nurses - 1.25 nursing contact hours (0.75 contact hours are in the area of pharmacology);
Pharmacists - 1.25 ACPE continuing education credits for pharmacists (0.125 CEUs)

To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

Contents of This CME/CE Activity

Legal Disclaimer

The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Copyright © 2008 Medscape.
Cephalon
Learning Objectives

Upon completion of this activity, participants will be able to:

  1. Identify the challenges associated with evaluating breakthrough pain.
  2. Recognize the impact that breakthrough pain has on morbidity and patient functioning.
  3. Design individualized treatment plans for patients in order to optimize treatment outcomes.
Authors and Disclosures

Neal E. Slatkin, MD
Disclosure: Neal E. Slatkin, MD, had disclosed that he has served as a consultant to Biodelivery Sciences International, Cephalon, and Archimedes.


Stephanie Kushner, PhD
Disclosure: Stephanie Kushner, PhD, has disclosed no relevant financial relationships.


Michelle I. Rhiner, RN, MSN, NP
Disclosure: Michelle I. Rhiner, RN, MSN, NP, has disclosed that she has received grants for clinical research from Cephalon and BEMA (BDSI). Ms. Rhiner has also disclosed that she has served as an advisor or consultant to Cephalon.
 
Medscape
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Medscape, LLC designates this educational activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

 
This Activity is sponsored by Medscape Continuing Education Provider Unit.

Medscape is an approved provider of continuing nursing education by the New York State Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.

Awarded 1.25 contact hour(s) of continuing nursing education for RNs and APNs; 0.75 contact hours are in the area of pharmacology.

Provider Number: 6FDKKC-PRV-05

Contact This Provider

 
ACPE logoMedscape is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Medscape designates this continuing education activity for 1.25 contact hour(s) (0.125 CEUs) (Universal Program Number 461-000-08-011-H01-P).

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.